Relationship between XPD 751 single nucleotide polymorphism and mFOLFOX6 chemotherapy efficacy and prognosis after colon cancer surgery

doi:10.3877/cma.j.issn.1674-0793.2020.02.006

Abstract

Abstract:

Objective

To investigate the relationship between single nucleotide polymorphism of DNA repair gene XPD 751 and the efficacy and prognosis of mFOLFOX6 chemotherapy after colon cancer surgery.

Methods

From June 2013 to June 2015, one hundred and five patients with colon cancer who underwent radical operation in People’s Hospital of Leshan City were prospectively selected as colon cancer group and 100 healthy persons as control group. Single nucleotide polymorphism and genotype distribution at XPD 751 locus was detected by DNA sequencing. The efficacy was evaluated at 6 months after mFOLFOX6 chemotherapy. Kaplan-Meier method and multivariate Cox regression were used to analyze the relationship between the polymorphism of the XPD 751 locus and the prognosis of patients.

Results

The disease control rate (DCR) of patients with XPD 751 AA genotype in colon cancer group was 86.44% (51/59), significantly higher than 65.22% (30/46) of CA/CC genotype (χ²=6.603, P<0.05). The 3-year overall survival rate and disease-free survival rate of the 105 patients were 69.52% and 29.52% respectively, and the AA genotype were 77.97% and 47.46%, higher than 58.70% and 6.52% of CA/CC genotype (χ²=4.712, 20.817, P=0.030, <0.01). The frequency of recurrence and metastasis in patients with AA genotype was significantly lower than that with CA/CC genotype (30.51% vs 52.17%, χ²=5.055, P=0.025). TNM staging and XPD 751 CA/CC genotype were risk factors for overall survival in patients with colon cancer (P=0.008, 0.017).

Conclusions

Colon cancer patients with XPD 751 CA/CC genotype show poor sensitivity to mFOLFOX6 chemotherapy, low disease-free survival rate and overall survival rate after radical operation. Detection of XPD 751 gene polymorphism is helpful to evaluate the efficacy and prognosis of chemotherapy in patients with colon cancer.

Key words: Colonic neoplasms, Excision repair cross complementing gene 2, Polymorphism, single nucleotide, Chemotherapy

Qing Qiao, Juan Liu, Aixin Wang, Danfei Yu, Fusheng Gou, Zhiyu Lin, Zhengwei Leng. Relationship between XPD 751 single nucleotide polymorphism and mFOLFOX6 chemotherapy efficacy and prognosis after colon cancer surgery[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(02): 103-106.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.02.006

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I02/103

Figures/Tables 4

References 13

[1]	罗芳，石君. 术后辅助化疗联合免疫治疗对结肠癌患者外周血T淋巴细胞亚群数量的影响[J]. 临床合理用药杂志, 2015, 8(6): 111-112.
[2]	Kosugi C, Koda K, Ishibashi K, et al. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage Ⅲ colon cancer: phase Ⅱ clinical study (The FACOS study)[J]. Int J Colorectal Dis, 2018, 33(6): 809-817.
[3]	Zheng DL, Tang GD, Chen YN, et al. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer[J]. Genet Mol Res, 2016, 15(2): 1-6.
[4]	陆俊国，李桃，徐燕飞, 等. ERCC2、RAD51和BAG-1基因多态性与晚期非小细胞肺癌铂类化疗敏感性的研究[J]. 现代肿瘤医学, 2015, 23(2): 203-205.
[5]	陈健，朱卫华，施民新, 等. ERCC2/XPD和XRCC1基因多态性与食管癌铂类药物化疗敏感性的关系[J]. 现代肿瘤医学, 2015, 23(20): 2936-2939.
[6]	Mehrzad J, Hashemi M, Jamshidi M, et al. Decreased expression of DNA repair genes (XRCC1 and XPD/ERCC2) in colorectal cancer in Iranian patients[J]. Int J Biol Sci, 2014, 10(2): 197-205.
[7]	滕雪，关尚为，刘朦朦, 等. 晚期非小细胞肺癌患者XPD基因多态性与铂类药物化疗临床疗效相关性的Meta分析[J]. 中国药房, 2016, 27(24): 3380-3384.
[8]	刘中华，陆海林. 着色性干皮病基因D单核苷酸多态性与铂类药物化疗后肾功能损伤的相关性[J]. 江苏医药, 2017, 43(19): 1422-1423.
[9]	Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer[J]. JAMA Oncol, 2017, 3(4): 464-471.
[10]	刘尚辉，范婷，肖莎, 等. 草酸铂治疗进展期结直肠癌疗效与ERCC1、ERCC2/XPD基因多态关联的Meta分析[J]. 中国现代医学杂志, 2015, 25(3): 1-6.
[11]	Khosa T, Aslam S, Mustafa S, et al. Association of single nucleotide polymorphisms in XRCC(194) and XPD(751) with age-related cataract[J]. Intel Ophthalmol, 2018, 38(3): 1135-1146.
[12]	陈雅敏，刘基巍，张昉. 结直肠癌基因XPD751和XPD312单核苷酸多态性与FOLFOX方案疗效相关性分析[J]. 中华肿瘤防治杂志, 2014, 21(24): 1946-1951.
[13]	Qian YY, Liu XY, Pei D, et al. The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A systemic review and Meta-analysis[J]. Asian Pac J Cancer Prev, 2014, 15(22): 9699-9706.

组别	例数	AA	CA	CC
对照组	100	62(62.00)	33(33.00)	5(5.00)
结肠癌组	105	59(56.19)	37(35.24)	9(8.57)
χ²值	?	1.325
P值	?	0.516

组别	例数	AA	CA	CC
对照组	100	62(62.00)	33(33.00)	5(5.00)
结肠癌组	105	59(56.19)	37(35.24)	9(8.57)
χ²值	?	1.325
P值	?	0.516

指标		例数	基因型		χ²值	P值
指标		例数	AA	CA/CC	χ²值	P值
性别		?	?	?	?	?
?	男	61	33	28	0.259	0.611
?	女	44	26	18	0.259	0.611
年龄(岁)		?	?	?	?	?
?	≥55	59	29	30	2.710	0.100
?	<55	46	30	16	2.710	0.100
组织学分型		?	?	?	?	?
?	腺癌	79	41	38	3.433	0.180
?	黏液癌	17	13	4
?	未分化癌	9	5	4
肿瘤形态分型		?	?	?	?	?
?	溃疡型	53	32	21	4.512	0.105
?	肿块型	30	19	11
?	浸润型	22	8	14
TNM分期		?	?	?	?	?
?	Ⅱ	51	31	20	0.850	0.357
?	Ⅲ	54	28	26	0.850	0.357
肿瘤直径(cm)		?	?	?	?	?
?	≥5	54	28	26	0.526	0.468
?	<5	51	31	20	0.526	0.468
癌胚抗原水平(μg/L)		?	?	?	?	?
?	>5	71	38	33	0.344	0.558
?	≤5	34	21	13	0.344	0.558

指标		例数	基因型		χ²值	P值
指标		例数	AA	CA/CC	χ²值	P值
性别		?	?	?	?	?
?	男	61	33	28	0.259	0.611
?	女	44	26	18	0.259	0.611
年龄(岁)		?	?	?	?	?
?	≥55	59	29	30	2.710	0.100
?	<55	46	30	16	2.710	0.100
组织学分型		?	?	?	?	?
?	腺癌	79	41	38	3.433	0.180
?	黏液癌	17	13	4
?	未分化癌	9	5	4
肿瘤形态分型		?	?	?	?	?
?	溃疡型	53	32	21	4.512	0.105
?	肿块型	30	19	11
?	浸润型	22	8	14
TNM分期		?	?	?	?	?
?	Ⅱ	51	31	20	0.850	0.357
?	Ⅲ	54	28	26	0.850	0.357
肿瘤直径(cm)		?	?	?	?	?
?	≥5	54	28	26	0.526	0.468
?	<5	51	31	20	0.526	0.468
癌胚抗原水平(μg/L)		?	?	?	?	?
?	>5	71	38	33	0.344	0.558
?	≤5	34	21	13	0.344	0.558

参数	B	SE	Wald	HR	95% CI	P值
TNM分期	1.201	0.806	2.220	3.324	2.051~5.386	0.008
CA/CC基因型	0.959	0.742	1.671	0.608	1.852~3.674	0.017

Please choose a citation manager

Content to export